More than 60% of participant dietary consumption plans showed no significant difference between omalizumab and multi-food oral immunotherapy success rates after 12 months MILWAUKEE, Feb. 22, 2026 ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
Please provide your email address to receive an email when new articles are posted on . Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% ...
Please provide your email address to receive an email when new articles are posted on . ADP101 includes 15 substances from the nine most common food allergens. 56% of participants with multiple ...
SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...
Due to its increasing prevalence and psychological and physical effects in recent decades, food allergy (FA) has become a chronic condition in the United States (US). Recent research highlights that ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
Participants in the OUtMATCH trial are allergic to peanuts and at least two other foods among milk, eggs, wheat, cashews, walnuts and hazelnuts. A clinical trial has found that the medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results